Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Appeal: Eloxatin Decision Gives District Courts Primacy On 30-Month Stays

Executive Summary

Brand companies have fewer tools to fight off generic challenges following a ruling that prevents them from reinstating a 30-month stay on FDA approvals if they initially lose the patent case in district court
Advertisement

Related Content

FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
Lovenox Lawsuit May Be Omen For Biosimilar Battles
Lovenox Lawsuit May Be Omen For Biosimilar Battles
Lovenox Lawsuit May Be Omen For Biosimilar Battles
Eloxatin's Wild Ride: Generics Back On The Market After Five-Day Stay Of Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS052483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel